Literature DB >> 16121446

Definition of primary mode of action of a combination product. Final rule.

.   

Abstract

The Food and Drug Administration (FDA) is amending its combination product regulations to define "mode of action'' (MOA) and "primary mode of action" (PMOA). Along with these definitions, the final rule sets forth an algorithm the agency will use to assign combination products to an agency component for regulatory oversight when the agency cannot determine with reasonable certainty which mode of action provides the most important therapeutic action of the combination product. Finally, the final rule will require a sponsor to base its recommendation of the agency component with primary jurisdiction for regulatory oversight of its combination product by using the PMOA definition and, if appropriate, the assignment algorithm. The final rule is intended to promote the public health by codifying the agency's criteria for the assignment of combination products in transparent, consistent, and predictable terms.

Mesh:

Substances:

Year:  2005        PMID: 16121446

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  4 in total

1.  Modular Fabrication of Intelligent Material-Tissue Interfaces for Bioinspired and Biomimetic Devices.

Authors:  John R Clegg; Angela M Wagner; Su Ryon Shin; Shabir Hassan; Ali Khademhosseini; Nicholas A Peppas
Journal:  Prog Mater Sci       Date:  2019-07-17

Review 2.  Regulatory perspectives of combination products.

Authors:  Jiaxin Tian; Xu Song; Yongqing Wang; Maobo Cheng; Shuang Lu; Wei Xu; Guobiao Gao; Lei Sun; Zhonglan Tang; Minghui Wang; Xingdong Zhang
Journal:  Bioact Mater       Date:  2021-09-07

3.  Regulation challenge of tissue engineering and regenerative medicine in China.

Authors:  Liang Chen; Chunren Wang; Tingfei Xi
Journal:  Burns Trauma       Date:  2013-09-18

4.  Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan.

Authors:  Kazuo Yano; Natsumi Watanabe; Kenichiro Tsuyuki; Taisuke Ikawa; Hiroshi Kasanuki; Masayuki Yamato
Journal:  Regen Ther       Date:  2014-11-11       Impact factor: 3.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.